DCAT Value Chain Insights’ Production to Prescription
DCAT
52 episodes
1 week ago
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
DCAT Value Chain Insights’ Production to Prescription
19 minutes
3 years ago
CDMOs/CMOs Ramp Up Biomanufacturing Capacity
Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding? For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) A roundup of expansion activityFujifilm Diosynth BiotechnologiesSamsung BiologicsLonzaBoehringer IngelheimThermo Fisher ScientificCatalentWuXi Biologics Sponsor: BIOVECTRA...
DCAT Value Chain Insights’ Production to Prescription
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
